InterMune (ITMN) Updates Expense Forecasts and Development Plans
More News related to ITMN
- InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
- InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
More News related to Corporate News
- Kinross Gold (KGC) Receives Authorization to Re-Commence Exploration on Project in Ecuador
- Sanofi-aventis (SNY) and Regeneron Pharmaceuticals (REGN) to Expand Global Collaboration
- Stryker (SYK) Announces Two Acquisitions
- Adobe (ADBE) Cutting 680 Full-Time Jobs to Align Costs with '10 Operating Plan
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
InterMune, Inc. (Nasdaq: ITMN) has completed a review of its research and development programs and infrastructure requirements. InterMune will implement a number of operational and infrastructure changes that, when fully implemented by 2008, are expected to reduce annual operating expenses by approximately $40 to $50 million.
The expense savings result from: 1) a reduction in staffing levels by 50%, or 116 full-time and contract positions affecting all departments; 2) a reduction of development, clinical and regulatory costs due to the termination of the INSPIRE trial; and 3) a reduction of SG&A expenses related to Actimmune.
Related Categories
Corporate NewsGuidance
Stocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
